Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
Suthinee IthimakinPongwut Danchaivijitr

Abstract

We assessed the efficacy of aprepitant (APR) or 10 or 5 mg OLN (OLN10 or OLN5) plus ondansetron and dexamethasone for chemotherapy-induced nausea/vomiting (CINV) prophylaxis in patients receiving high-emetogenic chemotherapy (HEC). Patients who received doxorubicin + cyclophosphamide or cisplatin were given intravenous ondansetron and dexamethasone prior to chemotherapy and oral dexamethasone on days 2-4 and randomized 1:1:1 to receive APR125 on day 1 and APR80 on days 2-3 or OLN10 or OLN5 on days 1-4. Matched placebo controls were used. The primary endpoint was no nausea in ≤ 120 h. Secondary endpoints included CINV severity, complete response (CR) rate, adverse effects (AE), and quality of life. Of 141 patients, 104 received AC and 37 received cisplatin. The no-nausea rates were 33% (APR), 43.2% (OLN10; p = 0.24), and 37% (OLN5; p = 0.87). Grades 2-4 nausea were experienced by fewer patients for OLN10 than for APR (24-120 h, 8.7% vs. 27.7%, respectively; p = 0.02; overall period, 19.6% vs. 40.4%, respectively; p = 0.03). The median visual analog scale nausea score from 24 to 120 h was significantly lower for OLN10 (2.3) than for APR (1.2, p = 0.03). The degrees of vomiting, CR, and AE were similar between the APR and OLN10 gr...Continue Reading

References

Jun 27, 2003·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·A R MartinC Lindley
Apr 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David G WarrFranck Skobieranda
Apr 21, 2011·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Suthinee IthimakinApirom Laocharoenkeat
Oct 8, 2016·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Lucksamon ThamlikitkulNopadol Soparattanapaisarn
Aug 17, 2018·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Suthan ChanthawongNathorn Chaiyakunapruk

❮ Previous
Next ❯

Citations

Nov 28, 2020·Current Treatment Options in Oncology·Mellar P Davis, Gareth J Sanger
Jan 15, 2021·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Ronald ChowRudolph M Navari
Jul 23, 2021·Pharmacogenomics and Personalized Medicine·Yilan JinQuanfu Li
Oct 7, 2021·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Ronald ChowElizabeth Horn Prsic

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Archives of Pharmacal Research
Archives of Pharmacal Research
Il Je Cho
Archives of Pharmacal Research
Keon Wook Kang
Archives of Pharmacal Research
Eun Sook Hwang
Archives of Pharmacal Research
Joo Young Lee
© 2021 Meta ULC. All rights reserved